Abstract
Insomnia is an incredibly common complaint occasionally affecting more than 40 % of the population. Insomnia can be a primary diagnosis or secondary to associated sleep, psychiatric or medical illnesses that induce disturbed sleep or nighttime discomfort. Insomnia is most commonly treated with medications including drugs of abuse/misuse (ethanol and cannabis), over-the-counter preparations (type 1 antihistamines, herbal remedies, and nutritional supplements), and prescription hypnotics used as recommended or as based on sedative side-effect profiles. Many of theses agents have significant abuse potential and toxicity, and limited effectiveness when used to treat insomnia. The newer alpha 1 GABA-A active medications for insomnia are efficacious, minimally addictive, have minimal side effects, are nontoxic in overdose, and can be used long term without altering sleep structure. When appropriately utilized these newer medications are safe for use in most patients with insomnia.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Pagel JF, Kram J. Insomnia: differential diagnosis and current treatment approach. In: Monti JM, Pandi-Perumal SR, Mohler H, editors. GABA and sleep—molecular, functional and clinical aspects. Basil: Springer; 2010. p. 363–82.
Atack J. Anxioselective compounds acting at the GABA A receptor benzodiazepine binding site. Curr Drug Targets CNS Neurol Disord. 2003;2:213–32.
Lossignol D. Euthanasia: medications and medical procedures. Rev Med Brux. 2008;29:435–40.
Ray WA, Griffen MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA. 1989;262:3303–7.
Ancoli-Israel S. Insomnia in the elderly: a review for the primary care practitioner. Sleep. 2000;23(S1):S23–30.
Richardson GS. Managing insomnia in the primary care setting: raising the issues. Sleep. 2000;23(1):S9–12.
Riemann D, Perlis ML. The treatment of chronic insomnia: a review of benzodiazepine receptor agonists and psychological and behavioral therapies. Sleep Med Rev. 2009;13(3):205–14.
George CFP. Perspectives in the management of insomnia in patients with chronic respiratory disorders. Sleep. 2000;23(S1):S31–5.
Kessler RC, McGonagle KC, Zhao S. Epidemiology of psychiatric disorders. Arch Gen Psychiatry. 1994;51:8–19.
Pagel JF, Parnes BL. Medications for the treatment of sleep disorders: an overview. Prim Care Companion J Clin Psychiatry. 2001;3(3):118–25.
Krystal A, Walsh J, Laska E, Caron J, Amato D, Wessel T, Roth T. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of randomized, double blind, placebo-controlled study in adults with chronic insomnia. Sleep. 2003;26(7):793–9.
Parker I. The big sleep. New Yorker. 2013;9:50–63.
Vester JC, Spence DW, Shahid A, Pandi-Perumal SR, Roth T. Zopiclone as positive control in studies examining the residual effects of hypnotic drugs on driving ability. Curr Drug Saf. 2013;6:209–18.
Sateia MJ, Doghramji K, Hauri PJ, Morin CM. Evaluation of chronic insomnia. Sleep. 2000;23(2):243–314.
Pagel JF. Medication effects on sleep. In: Pandi-Perumal SR, Ruoti RR, Kramer M, editors. Sleep and psychosomatic medicine. Andover, Hampshire: Informa UK, Ltd; 2007. p. 109–24.
Pagel JF. Medications that induce sleepiness. In: Lee-Chiong T, editor. Sleep a comprehensive handbook. Hoboken, NJ: Wiley; 2006. p. 175–82.
Jones BE, Jaffee SE, editors. Principles and practice of sleep medicine. 3rd ed. Philadelphia, PA: WB Saunders; 2000. p. 134–54. 1093–102.
Schwartz JH. Neurotransmitters. In: Kandel ER, Schwartz JH, Jessell TM, editors. Principles of neural science. 4th ed. New York, NY: McGraw Hill; 2000. p. 280–97.
Sateia MJ. Update on sleep and psychiatric disorders. Chest. 2009;135(5):1370–9.
Fava M, McCall WV, Krystal A, Wessel T, Ruben R, Caron J, Amato D, Roth T. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psycyiatry. 2006;59:1052–60.
Settle EC. Antidepressant drugs: disturbing and potentially dangerous adverse effects. J Clin Psychiatry. 1998;59(S16):25–9.
Pollack M, Kinrys G, Krystal A, McCall WV, Roth T, Schaefer K, Rubens R, Roach J, Huang H, Krishnan R. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry. 2008;65:5.
Lee-Chiong T, Pagel JF. Medication effects on sleep. In: Waldman SA, Terzic A, editors. Pharmacology and therapeutics—principles to practice. Philadelphia, PA: Saunders; 2009. p. 849–56.
Volz HP, Sturm Y. Antidepressant drugs and psychomotor performance. Neuropsychobiology. 1995;31:146–55.
Krystal AD. A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: the empirical basis for U. S. clinical practice. Sleep Med Rev. 2009;13:265–74.
Raskind MA, Peskind ER, Kanter ED, et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry. 2003;160(2):371–3.
Krystal AD, Durrnace HH, Scharf M, Jochelson P, Rogowski R, Ludington E, Roth T. Efficacy and safety of doxepin 1 mg and 3 mg in a 12 week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia. Sleep. 2013;33:1553–61.
Wirnow C, Gotter A, Cox C, Doran S, Tannenbaum P, Breslin M, et al. Promotion of sleep by suvorexant—a novel dual orexin receptor antagonist. J Neurogenet. 2013;25:52–61.
Pandi-Perumal SR, Spence DW, Verster JC, Srinivasan V, Brown GM, Cardinali DP, Hardeland R. Pharmacotherapy of insomnia with ramelteon: safety, efficacy and clinical applications. J Cent Nerv Syst Dis. 2013;3:51–65.
Stone BM, Turner C, Mills SL, Nicholson AN. Hypnotic activity of melatonin. Sleep. 2000;23(5):663–70.
Mamelak M, Black J, Montplaisir J, Ristanovic R. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep. 2004;27(7):1327–34.
Pagel JF. The treatment of parasomnias. In: Kushida C, editor. Handbook of sleep disorders. London: Informa; 2008. p. 523–34.
Pagel JF. The synchronous electrophysiology of conscious states. Dreaming. 2012;22:173–91.
Hart LL, Middleton RK, Schott WJ. Drug treatment for sleep apnea. DICP Ann Pharmacother. 1989;23:308–15.
O’Hanlon JF, Ramaekers JG. Antihistamine effects on actual driving performance in a standard driving test: a summary of Dutch experience. 1989–94. Allergy. 1995;50:234–42.
Stevinson C, Ernst E. Valerian for insomnia: a systematic review of randomized clinical trials. Sleep Med. 2000;1(2):91–9.
Brassington GS, King AC, Bliwise DL. Sleep problems as a risk factor for falls in a sample of community-dwelling adults aged 64–99 years. J Am Geriatr Soc. 2000;48(10):1234–40.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Pagel, J.F. (2014). Pharmacological Treatment of Insomnia. In: Pagel, J., Pandi-Perumal, S. (eds) Primary Care Sleep Medicine. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1185-1_9
Download citation
DOI: https://doi.org/10.1007/978-1-4939-1185-1_9
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-1184-4
Online ISBN: 978-1-4939-1185-1
eBook Packages: MedicineMedicine (R0)